BACKGROUND AND PURPOSE: Factors predictive of primary brain tumor outcome have
been studied extensively, although the prognostic value of radiologic data, such as MR …

BACKGROUND High grade astrocytomas account for approximately 40% of all primary
brain tumors. The median survival is approximately 8–10 months for patients with …

Twenty-five adults with recurrent malignant glioma were enrolled into a phase II clinical
study. All patients had undergone surgical resection and had failed radiotherapy and first …

Recurrent and progressive non-GBM gliomas are a diverse group of brain tumors that often
respond poorly to adjuvant chemotherapy treatment. Regional intra-arterial (IA) …

Fourty patients with malignant supratentorial gliomas received iterative intraarterial (IA)
infusions of ACNU, 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3 …

Thirty-three adult patients with anaplastic astrocytoma or glioblastoma multiforme, verified
between 1990 and 1997, received postoperative intra-arterial ACNU chemotherapy and …

Purpose: To assess the response of patients with recurrent malignant gliomas to intra-
arterial (IA) cisplatin. Methods: Eligibility criteria included patients with recurrent …

Background: Intra-arterial chemotherapy with carmustine (BCNU) and interstitial radiation
therapy with the use of stereotactically placed 125I sources are aggressive local therapies …

Recent clinical trial results suggest that anti-angiogenic therapy may be effective against
recurrent malignant glioma. Though these treatments prolong progression-free survival, the …

For the non-operable malignant glioma patients, prognosis remains poor, with a survival of 8
months for the glioblastomas (G), and 15 months for anaplastic astrocytomas (AA). 27 …